A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change (NCT05010031) | Clinical Trial Compass
RecruitingPhase 2
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
United States40 participantsStarted 2021-08-11
Plain-language summary
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
* Pathogenic mutation in ATM (somatic and germline allowed)
* ECOG performance status 0-2
* Age ≥ 18 years.
* Able to provide informed consent.
* Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
* Expected life expectancy of at least 6 months
Exclusion Criteria:
* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
* Serious medical co-morbidities precluding radiotherapy.
* Pregnant or breast-feeding women.
* Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.